Story perspectives

FDA's PreCheck Pilot Picks Seven Firms to Revive Pharma

6/30/2026

Summary

FDA Launches PreCheck

FDA launched PreCheck Pilot Program in 2026, selecting seven firms after a 2025 executive order by President Donald Trump.
Lilly’s Indiana plant will produce drug substance.
Regeneron’s New York site will make substance and injectables.
Amneal, Cellares, FUJIFILM Biotechnologies, Kriya Therapeutics and Kyowa Kirin will develop oncology therapies at three North Carolina sites and in New Jersey, New York, which Health Secretary Robert F. Kennedy Jr. said rebuilds pharmaceutical base.

Summary

Drugmakers Shift

Eli Lilly, Regeneron and drugmakers pledged billions to shift manufacturing to the United States and, April, agreed to cut Medicaid drug prices for three-year tariff exemptions.
The waivers offset higher costs of domestic facilities under the FDA’s PreCheck pilot.
President Donald Trump’s administration promoted the shift as securing the drug supply chain while keeping medicines affordable for patients.
Analysts say the package could reshape pricing for biologics and gene-therapy products.

1 of 2

FDA Launches PreCheck

FDA launched PreCheck Pilot Program in 2026, selecting seven firms after a 2025 executive order by President Donald Trump.
Lilly’s Indiana plant will produce drug substance.
Regeneron’s New York site will make substance and injectables.
Amneal, Cellares, FUJIFILM Biotechnologies, Kriya Therapeutics and Kyowa Kirin will develop oncology therapies at three North Carolina sites and in New Jersey, New York, which Health Secretary Robert F. Kennedy Jr. said rebuilds pharmaceutical base.

1 / 2